Condition: Shock · Cardiovascular Diseases · Infection · Sponsor: University Hospital, Strasbourg, France
Circulatory shocks (CS) are life-threatening, acute organ dysfunction. Advances in critical care medicine have decreased early hospital mortality, increasing the number of surviving patients. Regrettably, these survivors are at increased risk of new infections but also of cardiovascular disease. The investigators hypothesize that CS with multi-organ dysfunction is associated with premature senescence of endothelial cells and immune cells and promotes endothelial thrombogenicity and immunosenescence leading to cardiovascular disease and secondary infections. The aim of this work is therefore to evaluate the contribution of endothelial and leucocytes senescence to the occurrence of secondary events (infectious and cardiovascular) in patients with a CS. It will provide a better understanding of the pathogenesis of cardiovascular and immune diseases following a CS, likely to guide new management strategies to prevent their occurrence.
This description comes directly from the study's public registry record.
Morgane CLERC · 03 88 11 68 55 · morgane.clerc@chru-strasbourg.fr
Madoé JULIANS · 03 88 11 61 86 · madoe.julians@chru-strasbourg.fr
Always discuss trial participation with your own doctor first.
| Hôpitaux Universitaires de Strasbourg - Service de Réanimation médicale du NHC | Strasbourg, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03559569